Lexaria Updates Progress on Human Study #7

(TheNewswire)

Kelowna, British Columbia –TheNewswire - May 5, 2026 - LexariaBioscience Corp. (NASDAQ: LEXX) (“Lexaria” or the “Company”),a global innovator in oral drug delivery platforms, provides this update on Human PilotStudy #7 (GLP-1-H26-7) that will evaluate 2 oralDehydraTECH-semaglutide (“DHT-sema”) compositions against NovoNordisk’s® commercially available Wegovy® tablets (the“Study”).

Submissions have now been entered to formally requestthe required ethics approval from an independent review board. Finallaboratory tablet composition work and commercial-scale manufacturingfor the DHT-sema test articles for the Study have been completed withthird-party independent lab quality-control (“QC”) testing of suchtest articles currently underway.  It is anticipated that receipt ofethics approval, completion of QC testing and packaging of thequalified test articles (the “Pre-Dosing Tasks”) will occur byearly June.

The design of this Study is complete, subject to anymodifications which may or may not be required by the ethicsreviewers.  The Study is planned to be a 5-week parallel groupdesign, investigating 3 separate arms to assess safety &tolerability and pharmacokinetic (“PK”) properties that willcompare salcaprozate sodium (“SNAC”)-inclusive DHT-sema tablet andcapsule formulations to commercially available Wegovy® tablets.  TheStudy will be conducted under fasted pre-dose conditions. Lexariahopes to preserve the superior safety and tolerability profiles asevidenced in previous Lexaria GLP-1 studies such as Human Study #4(GLP-1-H25-4), combined with PK performancethat matches or exceeds that of the commercial oral tablet as alsoevidenced in previous Lexaria SNAC-inclusive DHT-sema studies such asHuman Studies #1 and #2 (GLP-1-H24-1and GLP-1-H24-2;which, incidentally, also evidenced noteworthy safety and tolerabilityprofiles).

The results of this Study are expected to be carefullyreviewed by the pharmaceutical industry in order to evaluate thepossibility of entering into commercial relationships focused onLexaria’s proprietary DehydraTECH technology.

What’s New?

This Study explores several new DehydraTECHenhancements not previously evaluated, which include but are notlimited to the following 2 main improvements:

1. First, an oral tablet DHT-sema composition will be used byLexaria for the first time, as opposed to only the capsulecompositions included in all our previous DHT glucagon-like peptide-1(“GLP-1”) studies. Novo Nordisk’s® Rybelsus® and Wegovy® oralsemaglutide medications both use specially formulated tablets designedto temporarily adhere to the stomach lining and disintegrate anddissolve releasing agents in a focal manner that aids in optimizingabsorption of the active ingredient – semaglutide – into the humanbody. For the first time ever, Lexaria has attempted to mimic andintegrate certain properties of this Rybelsus®/Wegovy® tabletdelivery modality into its DHT-sema tablets. Lexaria believes this mayincrease the likelihood of subsequent commercial pharmaceuticalrelationships. 

2. Second, both the Lexaria DHT-sema tablet and capsuletest articles will be formulated with SNAC, which will be the firsttime these formulations are evaluated over a multi-dose, multi-weektime period in humans. The 5-week dosing duration of the Study isexpected to be long enough to reach so-called steady-state,which is when drug concentrations in the body reach a constantconcentration. Earlier DHT-sema human pilot studies GLP-1-H24-1 andGLP-1-H24-2, as noted above, that Lexaria conducted in 2024 and 2025that also used SNAC (but did not use tablets), were limited bysingle-dose study designs; therefore, of much shorter duration. NovoNordisk’s® branded Rybelsus® and Wegovy® semaglutide basedproducts are both formulated with SNAC. 

Lexaria will update its stakeholders once thePre-Dosing Tasks have been achieved. Based on the expected timelines,Lexaria anticipates dosing to begin in mid-June. The Study is fully funded from existing corporate resources.

About Lexaria Bioscience Corp. &DehydraTECH

DehydraTECH™ is Lexaria’s patented drug deliveryformulation and processing platform technology which improves the waya wide variety of drugs enter the bloodstream, always through oraldelivery. DehydraTECH has repeatedly evidenced the ability to increasebio-absorption, reduce side-effects, and deliver some drugs moreeffectively across the blood brain barrier. Lexaria operates alicensed in-house research laboratory and holds a robust intellectualproperty portfolio with 65 patents granted and additional patentspending worldwide. For more information, please visitwww.lexariabioscience.com.

CAUTION REGARDING FORWARD-LOOKINGSTATEMENTS

This press release includes forward-looking statements.Statements as such term is defined under applicable securities laws.These statements may be identified by words such as “anticipate,”“if,” “believe,” “plan,” “estimate,” “expect,”“intend,” “may,” “could,” “should,” “will,” andother similar expressions. Such forward-looking statements in thispress release include, but are not limited to, statements by theCompany relating to the intended use of proceeds from the offering andrelating to the Company’s ability to carry out research initiatives,receive regulatory approvals or grants or experience positive effectsor results from any research or study. Such forward-looking statementsare estimates reflecting the Company’s best judgment based uponcurrent information and involve a number of risks and uncertainties,and there can be no assurance that the Company will actually achievethe plans, intentions, or expectations disclosed in theseforward-looking statements. As such, you should not place unduereliance on these forward-looking statements. Factors which couldcause actual results to differ materially from those estimated by theCompany include, but are not limited to, market and other conditions,government regulation and regulatory approvals, managing andmaintaining growth, the effect of adverse publicity, litigation,competition, scientific discovery, the patent application and approvalprocess, potential adverse effects arising from the testing or use ofproducts utilizing the DehydraTECH technology, the Company’s abilityto maintain existing collaborations and realize the benefits thereof,delays or cancellations of planned R&D that could occur related topandemics or for other reasons, and other factors which may beidentified from time to time in the Company’s public announcementsand periodic filings with the US Securities and Exchange Commission onEDGAR. The Company provides links to third-party websites only as acourtesy to readers and disclaims any responsibility for thethoroughness, accuracy or timeliness of information at third-partywebsites. There is no assurance that any of Lexaria’s postulateduses, benefits, or advantages for the patented and patent-pendingtechnology will in fact be realized in any manner or in any part. Nostatement herein has been evaluated by the Food and DrugAdministration (FDA). Lexaria-associated products are not intended todiagnose, treat, cure or prevent any disease. Any forward-lookingstatements contained in this release speak only as of the date hereof,and the Company expressly disclaims any obligation to update anyforward-looking statements or links to third-party websites containedherein, whether as a result of any new information, future events,changed circumstances or otherwise, except as otherwise required bylaw.

INVESTOR CONTACT:

George Jurcic – Head of Investor Relations

ir@lexariabioscience.com

Phone: 250-765-6424, ext 202

Copyright (c) 2026 TheNewswire - All rights reserved.